Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)

NCT05538533 | Active Not Recruiting DMC FDA Device

• 1 other identifier: PRO44863
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase 1 study to determine the safety of a condensed preoperative radiation regimen (10, 7, or 5 fractions) for the management of head and neck squamous cell carcinoma.

Conditions

Head and Neck Cancer

Keywords

Head and Neck Cancer; Hypofractionated Preoperative Radiation; Time-to-Event Continuous Reassessment Methodology; TITE-CRM

Outcome Measures

Primary Outcomes (3)

• The number of subjects with a dose-limiting toxicity related to inoperability.

  Inoperability after HyPR-HN, is defined as an inability to proceed to surgery within eight weeks of radiation.

  8 Weeks

• The number of subjects with a dose-limiting toxicity related to perioperative complication rates.

  Severe perioperative complication rates, defined as unacceptable toxicity from initiation of treatment until 30 days postoperatively (grade 4/5 toxicity) probably or definitely related to treatment.

  8 Weeks

• The number of subjects with severe delayed toxicity.

  Severe delayed toxicities, defined as any unacceptable toxicity (grade 4+) after 30 days postoperatively until one year after initiation of HyPR-HN probably or definitely related to treatment.

  Up to one year

Secondary Outcomes (2)

• Overall survival

  One year

• Recurrence-free Survival

  One year

Study Arms (3)

46 Gray (Gy)

EXPERIMENTAL

46 gy of radiation therapy will be administered in 10 fractions.

Radiation: 46 Gy Radiation Therapy

40 Gray (Gy)

EXPERIMENTAL

40 gy of radiation therapy will be administered in 7 fractions.

Radiation: 40 Gy Radiation Therapy

35 Gray (Gy)

EXPERIMENTAL

35 gy of radiation therapy will be administered in 5 fractions.

Radiation: 35 Gy Radiation Therapy

Interventions

46 Gy Radiation Therapy RADIATION

Dose per fraction of 4.6.

46 Gray (Gy)

40 Gy Radiation Therapy RADIATION

Dose per fraction 5.7.

40 Gray (Gy)

35 Gy Radiation Therapy RADIATION

Dose per fraction 7.0.

35 Gray (Gy)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients 18 years or older with surgically resectable, Human papillomavirus (HPV) -negative squamous cell carcinoma of the head and neck (squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, nasal cavity or paranasal sinuses). Resectability will be determined by the treating surgeon. Patients must have locoregionally advanced disease defined by clinical T3-4 staging and/or clinical node positive staging. Patients may also be eligible if they meet one of the following criteria:
• Clinical T2N0 disease with perineural invasion identified on a pretreatment biopsy.
• Clinical T2N0 disease with lymphovascular space invasion identified on a pretreatment biopsy.
• Clinical T2N0 oral cavity cancer with clinical, biopsy, or radiographic depth of invasion of at least 5 mm.
• Zubrod performance status 0-2.
• Patients must have the psychological ability and general health that permits completion of the study requirements and required follow-up.
• Female patients must meet one of the following:
• Postmenopausal for at least one year before the screening visit, OR
• Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
• If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND
• Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptom-thermal, postovulation methods\] and withdrawal are not acceptable contraception methods).
• Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:
• Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
• Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR
• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptom-thermal, postovulation methods\] and withdrawal are not acceptable methods of contraception.

You may not qualify if:

• Radiographic evidence of extranodal extension.
• Patients with laryngeal involvement who are candidates for non-surgical laryngeal preservation as deemed by a surgeon and/or radiation oncologist. These patients include, but are not limited to, those with T1-T3 laryngeal cancer who do not have pretreatment tracheostomy and/or feeding tube or those with base of tongue/hypopharyngeal cancers with laryngeal involvement without cartilage invasion or pretreatment tracheostomy and/or feeding tube.
• HPV-positive squamous cell carcinoma.
• Prior invasive malignancy within the past three years (except for non-melanomatous skin cancer, and early stage treated prostate cancer).
• Life expectancy less than 12 months.
• Zubrod performance status ≥ 3.
• Patients with prior radiation therapy to the head and neck (Note: Prior external beam radiotherapy is excluded, but iodine-131 is allowed).
• Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer.
• Body weight ≤ 30 kg.
• Any of the following severe laboratory abnormalities within 14 days of registration, unless corrected prior to it: sodium \< 130 mmol/L or \> 155 mmol/L; potassium \< 3.5 mmol/L or \> 6 mmol/L; fasting glucose \< 40 mg/dL or \> 400 mg/dL; serum calcium (ionized or adjusted for albumin) \< 7 mg/dL or \> 12.5 mg/dL; magnesium \< 0.9 mg/dL or \> 3 mg/dL.
• Unstable angina and/or congestive heart failure requiring hospitalization within three months prior to step 1 registration.
• Transmural myocardial infarction within three months prior to step 1 registration.
• Medical or psychiatric illness which would compromise the patient's ability to tolerate treatment or limit compliance with study requirements.

Sponsors & Collaborators

• Medical College of Wisconsin: lead

Study Sites (1)

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

MeSH Terms

Conditions

Head and Neck Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms

Study Officials

• Joseph Zenga, MD

  Medical College of Wisconsin

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Model Details: This study will use a time-to-event continual reassessment method (TITE-CRM) for assigning subjects to the radiation therapy dosages.

Study Record Dates

• First Submitted: September 9, 2022
• First Posted: September 14, 2022
• Study Start: January 6, 2023
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: March 10, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)